<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950637</url>
  </required_header>
  <id_info>
    <org_study_id>GAPP2</org_study_id>
    <secondary_id>U1111-1136-2536</secondary_id>
    <nct_id>NCT01950637</nct_id>
  </id_info>
  <brief_title>GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus</brief_title>
  <official_title>GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted Asia, Europe and North America. The aim of this study is to describe
      insulin therapy adherence and the burden of non-adherence on patient functioning, well-being
      and diabetes management.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Basal insulin dosing irregularities: frequency of missed doses, mistimed doses, or reduced doses (patient questionnaire)</measure>
    <time_frame>In the past 30 days prior to the day when responding to the online questionnaire</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Level of patient dosing irregularity: missed, mistimed and reduced dose (HCP questionnaire)</measure>
    <time_frame>Day 1 (when responding to the online questionnaire)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of intentional dosing irregularities and reasons for this behaviour</measure>
    <time_frame>Day 1 (when responding to the online questionnaire)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of dosing irregularity on functional well-being</measure>
    <time_frame>Day 1 (when responding to the online questionnaire)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of self-treated hypoglycaemia</measure>
    <time_frame>In the past 30 days prior to the day when responding to the online questionnaire</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">4000</enrollment>
  <condition>Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Patients with type 2 diabetes mellitus (T2DM)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthcare professionals (HCPs)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>No treatment given</intervention_name>
    <description>Completion of 90-item online questionnaire.</description>
    <arm_group_label>Patients with type 2 diabetes mellitus (T2DM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>survey</intervention_name>
    <description>Completion of 58-item online questionnarie.</description>
    <arm_group_label>Healthcare professionals (HCPs)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Insulin treated patients with type 2 diabetes, and HCPs involved in the treatment,
        management of diabetes and care of patients with type 2 diabetes.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  PATIENTS WITH T2DM:

          -  Diagnosed with type 2 diabetes by a healthcare professional

          -  Currently being treated with insulin medication, excluding premix insulin treatment

          -  Age at least 40 years

          -  Diagnosed as having type 2 diabetes over the age of 40

          -  HCPs:

          -  Primary care physician, diabetes specialist (diabetologist/endocrinologist) or
             diabetes specialist nurse/diabetes nurse educator

          -  Have a minimum of 2 years experience within current speciality

          -  See a minimum of 20 type 2 diabetes patients per month (40 for diabetes specialists),
             of which at least 10 per month must be on modern (analogue) inulins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mississauga</city>
        <zip>L4W 4XI</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Copenhagen S</city>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mainz</city>
        <zip>55127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>1000005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Crawley</city>
        <zip>RH11 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Japan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Brod M, Rana A, Barnett AH. Impact of self-treated hypoglycaemia in type 2 diabetes: a multinational survey in patients and physicians. Curr Med Res Opin. 2012 Dec;28(12):1947-58. doi: 10.1185/03007995.2012.743457. Epub 2012 Nov 14.</citation>
    <PMID>23150950</PMID>
  </results_reference>
  <results_reference>
    <citation>Brod M, Rana A, Barnett AH. Adherence patterns in patients with type 2 diabetes on basal insulin analogues: missed, mistimed and reduced doses. Curr Med Res Opin. 2012 Dec;28(12):1933-46. doi: 10.1185/03007995.2012.743458. Epub 2012 Nov 14.</citation>
    <PMID>23150949</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

